[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342397-105":59,"doc-detail-342397-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inhibition-of-autocrine-hgf-maturation-overcomes-cetuximab-resistance-in-colorectal-cancer","Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer","","Although receptor tyrosine kinase (RTK) amplifications and mutations can drive oncogenesis, many cancers keep RTKs in a moderate, wild-type state while relying on ligands to sustain tumorigenesis, including resistance to anti-RTK therapies. The study shows that MET and RON ligands (HGF and HGFL) are produced as inactive precursors activated by cellular proteases, and that HGF/HGFL protease inhibitors counter both de novo and acquired cetuximab resistance in colorectal cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inhibition-of-autocrine-hgf-maturation-overcomes-cetuximab-resistance-in-colorectal-cancer/342397/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inhibition-of-autocrine-hgf-maturation-overcomes-cetuximab-resistance-in-colorectal-cancer/342397.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do HGF and HGFL contribute to cetuximab resistance in colorectal cancer?","Question",{"text":112,"@type":113},"HGF/HGFL are synthesized as inactive precursors activated by cellular proteases. HGF overexpression is necessary and sufficient to induce cetuximab resistance and loss of polarity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic strategies can overcome cetuximab resistance described in the study?",{"text":117,"@type":113},"Downstream MET inhibition with crizotinib and upstream protease inhibitors can overcome HGF-induced cetuximab resistance. Newly generated HGF/HGFL protease inhibitors also counter both de novo and acquired resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does HAI-1 play in cetuximab resistance?",{"text":121,"@type":113},"HAI-1, an endogenous inhibitor of HGF proteases, is downregulated in colorectal cancer and shows increased genomic methylation linked to poor prognosis. Its expression correlates with cetuximab response, and adding recombinant HAI-1 overcomes resistance in CC-HGF cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342397,1790177992,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Cellular and Molecular Life Sciences (2024) 81:28  \n[https://doi.org/10.1007/s00018-023-05071-5](https://doi.org/10.1007/s00018-023-05071-5) Cellular and Molecular Life Sciences  \nInhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer  \nVivian Truong Jones1,2 · Ramona Graves‑Deal1 · Zheng Cao1 · Galina Bogatcheva1 · Marisol A. Ramirez3,4 ·  \nSarah J. Harmych1,5 · James N. Higginbotham1 · Vineeta Sharma1 · Vishnu C. Damalanka6 · Claudia C. Wahoski1,7 · Neeraj Joshi1 · Maria Johnson Irudayam1 · Joseph T. Roland8 · Gregory D. Ayers3 · Qi Liu3,4 · Robert J. Coffey1,9 · James W. Janetka6 · Bhuminder Singh1,9  \nReceived: 24 August 2023 / Revised: 27 October 2023 / Accepted: 27 November 2023 © The Author(s) 2024  \nAbstract  \nAlthough amplifications and mutations in receptor tyrosine kinases (RTKs) act as bona fide oncogenes, in most cancers, RTKs maintain moderate expression and remain wild-type. Consequently, cognate ligands control many facets of tumorigenesis, including resistance to anti-RTK therapies. Herein, we show that the ligands for the RTKs MET and RON, HGF and HGFL, respectively, are synthesized as inactive precursors that are activated by cellular proteases. Our newly generated HGF/HGFL protease inhibitors could overcome both de novo and acquired cetuximab resistance in colorectal cancer (CRC) . Conversely, HGF overexpression was necessary and sufficient to induce cetuximab resistance and loss of polarity. Moreover, HGF-induced cetuximab resistance could be overcome by the downstream MET inhibitor, crizotinib, and upstream protease inhibitors. Additionally, HAI-1, an endogenous inhibitor of HGF proteases,(i) was downregulated in CRC,(ii) exhibited increased genomic methylation that correlated with poor prognosis,(iii) HAI-1 expression correlated with cetuximab response in a panel of cancer cell lines, and (iv) exogenous addition of recombinant HAI-1 overcame cetuximab resistance in CC-HGF cells. Thus, we describe a targetable, autocrine HAI-1/Protease/HGF/MET axis in cetuximab resistance in CRC.  \nKeywords Colorectal cancer · Drug resistance · Cetuximab · Crizotinib · EGFR · MET · HGF · HAI-1 · 3D culture · Protease inhibition  \nBackground  \nColorectal cancer (CRC) is the second deadliest cancer both in the United States and globally [1]. About 20% of patients are diagnosed with metastatic disease despite improvements  \nin screening [2] . Often, these individuals will experience no signs or symptoms of the disease until it is discovered ata late stage. Although early stages of CRC have promising 5-year survival rates, the 5-year survival rate for stage IV is a meager 14%[2] . The addition of targeted therapies such ascetuximab and panitumumab has prolonged overall survival  \nVivian Truong Jones and Ramona Graves-Deal are co-first authors.  \n* Bhuminder Singh [bhuminder.singh@vumc.org](bhuminder.singh@vumc.org)  \n1 Department of Medicine, Vanderbilt University Medical Center, 10465J, MRB IV, 2213 Garland Avenue, Nashville, TN 37232-0441, USA  \n2 Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA  \n3 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA  \n4 Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA  \n5 Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA  \n6 Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, MO 63110, USA  \n7 Program in Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA  \n8 Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA  \n9 Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA  \nrates for metastatic CRC to a median of 30 months compared to 20 months with conventional chemotherapy [3–7] .  \nCetuximab and panitumumab are monoclonal antibodies used to inhibit epidermal growth","cbCaidJAvQPp515p","https://ap.wps.com/l/cbCaidJAvQPp515p","pdf",2278145,18,"English","# Abstract\n# Background","[{\"question\":\"How do HGF and HGFL contribute to cetuximab resistance in colorectal cancer?\",\"answer\":\"HGF/HGFL are synthesized as inactive precursors activated by cellular proteases. HGF overexpression is necessary and sufficient to induce cetuximab resistance and loss of polarity.\"},{\"question\":\"What therapeutic strategies can overcome cetuximab resistance described in the study?\",\"answer\":\"Downstream MET inhibition with crizotinib and upstream protease inhibitors can overcome HGF-induced cetuximab resistance. Newly generated HGF/HGFL protease inhibitors also counter both de novo and acquired resistance.\"},{\"question\":\"What role does HAI-1 play in cetuximab resistance?\",\"answer\":\"HAI-1, an endogenous inhibitor of HGF proteases, is downregulated in colorectal cancer and shows increased genomic methylation linked to poor prognosis. Its expression correlates with cetuximab response, and adding recombinant HAI-1 overcomes resistance in CC-HGF cells.\"}]","Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer | PDF",1790046437,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14be85096060fb534d50571774c2c690.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64530da39816789e778b6214b70dc248.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50bd00f675e0a552d39bbf1f81dc9f60.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d02ad03768969f4d8e0580e4f5f46e1.webp",980,1301]